Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
2 recherche sur le mot-clé 'Gamma-aminobutyric acid (GABA)'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Cerebro-Cerebellar Functional Connectivity is Associated with Cerebellar Excitation-Inhibition Balance in Autism Spectrum Disorder / J. P. HEGARTY in Journal of Autism and Developmental Disorders, 48-10 (October 2018)
[article]
Titre : Cerebro-Cerebellar Functional Connectivity is Associated with Cerebellar Excitation-Inhibition Balance in Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : J. P. HEGARTY, Auteur ; D. J. WEBER, Auteur ; C. M. CIRSTEA, Auteur ; David Q. BEVERSDORF, Auteur Article en page(s) : p.3460-3473 Langues : Anglais (eng) Mots-clés : Cerebellum Dorsolateral prefrontal cortex Functional connectivity Gamma-aminobutyric acid (GABA) Glutamate Magnetic resonance spectroscopy (MRS) Index. décimale : PER Périodiques Résumé : Atypical functional connectivity (FC) and an imbalance of excitation-to-inhibition (E/I) have been previously reported in cerebro-cerebellar circuits in autism spectrum disorder (ASD). The current investigation used resting state fMRI and proton magnetic resonance spectroscopy ((1)H-MRS) to examine the relationships between E/I (glutamate + glutamine/GABA) and FC of the dorsolateral prefrontal cortex and posterolateral cerebellar hemisphere from 14 adolescents/adults with ASD and 12 age/sex/IQ-matched controls. In this pilot sample, cerebro-cerebellar FC was positively associated with cerebellar E/I and listening comprehension abilities in individuals with ASD but not controls. Additionally, a subgroup of individuals with ASD and low FC (n = 5) exhibited reduced E/I and impaired listening comprehension. Thus, altered functional coherence of cerebro-cerebellar circuits in ASD may be related with a cerebellar E/I imbalance. En ligne : http://dx.doi.org/10.1007/s10803-018-3613-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=369
in Journal of Autism and Developmental Disorders > 48-10 (October 2018) . - p.3460-3473[article] Cerebro-Cerebellar Functional Connectivity is Associated with Cerebellar Excitation-Inhibition Balance in Autism Spectrum Disorder [Texte imprimé et/ou numérique] / J. P. HEGARTY, Auteur ; D. J. WEBER, Auteur ; C. M. CIRSTEA, Auteur ; David Q. BEVERSDORF, Auteur . - p.3460-3473.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 48-10 (October 2018) . - p.3460-3473
Mots-clés : Cerebellum Dorsolateral prefrontal cortex Functional connectivity Gamma-aminobutyric acid (GABA) Glutamate Magnetic resonance spectroscopy (MRS) Index. décimale : PER Périodiques Résumé : Atypical functional connectivity (FC) and an imbalance of excitation-to-inhibition (E/I) have been previously reported in cerebro-cerebellar circuits in autism spectrum disorder (ASD). The current investigation used resting state fMRI and proton magnetic resonance spectroscopy ((1)H-MRS) to examine the relationships between E/I (glutamate + glutamine/GABA) and FC of the dorsolateral prefrontal cortex and posterolateral cerebellar hemisphere from 14 adolescents/adults with ASD and 12 age/sex/IQ-matched controls. In this pilot sample, cerebro-cerebellar FC was positively associated with cerebellar E/I and listening comprehension abilities in individuals with ASD but not controls. Additionally, a subgroup of individuals with ASD and low FC (n = 5) exhibited reduced E/I and impaired listening comprehension. Thus, altered functional coherence of cerebro-cerebellar circuits in ASD may be related with a cerebellar E/I imbalance. En ligne : http://dx.doi.org/10.1007/s10803-018-3613-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=369 STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study / Craig ERICKSON in Journal of Autism and Developmental Disorders, 44-4 (April 2014)
[article]
Titre : STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study Type de document : Texte imprimé et/ou numérique Auteurs : Craig ERICKSON, Auteur ; Jeremy M. VEENSTRA-VANDERWEELE, Auteur ; Raun D. MELMED, Auteur ; James T. MCCRACKEN, Auteur ; Lawrence D. GINSBERG, Auteur ; Linmarie SIKICH, Auteur ; Lawrence SCAHILL, Auteur ; Maryann CHERUBINI, Auteur ; Peter ZAREVICS, Auteur ; Karen WALTON-BOWEN, Auteur ; Randall L. CARPENTER, Auteur ; Mark F. BEAR, Auteur ; Paul P. WANG, Auteur ; Bryan H. KING, Auteur Année de publication : 2014 Article en page(s) : p.958-964 Langues : Anglais (eng) Mots-clés : STX209 Arbaclofen Gamma-aminobutyric acid (GABA) Autism spectrum disorder Clinical trial Index. décimale : PER Périodiques Résumé : STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder—Not Otherwise Specified, and a score ?17 on the Aberrant Behavior Checklist (ABC)—Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted. En ligne : http://dx.doi.org/10.1007/s10803-013-1963-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228
in Journal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.958-964[article] STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study [Texte imprimé et/ou numérique] / Craig ERICKSON, Auteur ; Jeremy M. VEENSTRA-VANDERWEELE, Auteur ; Raun D. MELMED, Auteur ; James T. MCCRACKEN, Auteur ; Lawrence D. GINSBERG, Auteur ; Linmarie SIKICH, Auteur ; Lawrence SCAHILL, Auteur ; Maryann CHERUBINI, Auteur ; Peter ZAREVICS, Auteur ; Karen WALTON-BOWEN, Auteur ; Randall L. CARPENTER, Auteur ; Mark F. BEAR, Auteur ; Paul P. WANG, Auteur ; Bryan H. KING, Auteur . - 2014 . - p.958-964.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.958-964
Mots-clés : STX209 Arbaclofen Gamma-aminobutyric acid (GABA) Autism spectrum disorder Clinical trial Index. décimale : PER Périodiques Résumé : STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder—Not Otherwise Specified, and a score ?17 on the Aberrant Behavior Checklist (ABC)—Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted. En ligne : http://dx.doi.org/10.1007/s10803-013-1963-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228